Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Cochrane Database Syst Rev ; (8): CD007448, 2012 Aug 15.
Artigo em Inglês | MEDLINE | ID: mdl-22895960

RESUMO

BACKGROUND: Although the exact aetiology of necrotising enterocolitis (NEC) remains unknown, research suggests that it is multifactorial; suspected pathophysiological mechanisms include immaturity, intestinal ischaemia, disruption of intestinal mucosal integrity, formula feeding, hyperosmolar load to the intestine, infection and bacterial translocation. Various antibiotic regimens have been widely used in the treatment of NEC. OBJECTIVES: To compare the efficacy of different antibiotic regimens on mortality and the need for surgery in neonates with NEC. SEARCH METHODS: Searches were made of the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library, Issue 1, 2012), Oxford Database of Perinatal Trials, MEDLINE (1966 to February 2012), EMBASE (1980 to February 2012) and CINAHL (1982 to February 2012). SELECTION CRITERIA: All randomised and quasi-randomised controlled trials where antibiotic regimens were used for treatment of NEC. DATA COLLECTION AND ANALYSIS: Eligibility of studies for inclusion was assessed independently by each review author. The criteria and standard methods of the Cochrane Neonatal Review Group were used to assess the methodological quality of the included trials. MAIN RESULTS: Two trials met the inclusion criteria. Faix 1988 randomised 42 premature infants with radiological diagnosis of NEC. Infants were randomised to receive either intravenous ampicillin and gentamicin or ampicillin, gentamicin and clindamycin. Hansen 1980 randomised 20 infants with NEC to receive intravenous ampicillin and gentamicin with or without enteral gentamicin.In the study by Faix 1988, there were no statistical differences in mortality (RR 1.10; 95% CI 0.32 to 3.83) or bowel perforation (RR 2.20; 95% CI 0.45 to 10.74) between the two groups although there was a trend towards higher rate of strictures in the group that received clindamycin (RR 7.20; 95% CI 0.97 to 53.36).The Hansen 1980 study showed no statistically significant difference in death, bowel perforation or development of strictures. AUTHORS' CONCLUSIONS: There was insufficient evidence to recommend a particular antibiotic regimen for the treatment of NEC. There were concerns about adverse effects following the usage of clindamycin, related to the development of strictures. To address this issue a large randomised controlled trial needs to be performed.


Assuntos
Antibacterianos/uso terapêutico , Enterocolite Necrosante/tratamento farmacológico , Doenças do Prematuro/tratamento farmacológico , Ampicilina/uso terapêutico , Clindamicina/uso terapêutico , Quimioterapia Combinada/métodos , Enterocolite Necrosante/mortalidade , Gentamicinas/uso terapêutico , Humanos , Recém-Nascido , Recém-Nascido Prematuro , Doenças do Prematuro/mortalidade , Perfuração Intestinal/prevenção & controle , Ensaios Clínicos Controlados Aleatórios como Assunto
2.
Indian J Lepr ; 72(4): 443-9, 2000.
Artigo em Inglês | MEDLINE | ID: mdl-11212478

RESUMO

In this retrospective study, sensitivity of organisms cultured from ulcers of leprosy patients without and with diabetes mellitus, diabetic patients without leprosy and patients with ulcers from other causes was examined. The profile of organisms grown from these groups of patients did not differ significantly. However, there was a high prevalence of organisms like Proteus, E. coli and Enterococcus in the ulcers of leprosy patients indicating faecal contamination of the ulcers. Co-trimaxazole and tetracycline were of little value in the treatment of these ulcers. We therefore recommend that in situations where there is no culture facility, the patients be started on a course of penicillin and gentamycin. If these antibiotics fail, it would be necessary to use more advanced antibiotics like norfloxacin, amikacin and ciprofloxacin.


Assuntos
Bactérias/isolamento & purificação , Infecções Bacterianas/microbiologia , Úlcera do Pé/microbiologia , Hanseníase/complicações , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Antibacterianos/uso terapêutico , Bactérias/classificação , Criança , Complicações do Diabetes , Feminino , Úlcera do Pé/tratamento farmacológico , Gentamicinas/uso terapêutico , Humanos , Masculino , Pessoa de Meia-Idade , Penicilinas/uso terapêutico , Estudos Retrospectivos , Supuração/microbiologia
3.
Eur J Clin Microbiol Infect Dis ; 13(12): 1069-74, 1994 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-7889972

RESUMO

Systemic strongyloidiasis is a rare but serious complication of intestinal strongyloidiasis. The condition occurs mainly in immunosuppressed patients and has a significant mortality rate. A case of systemic strongyloidiasis is described in a patient who received systemic steroid treatment, and a short review of the literature is given. The increased use of immunosuppressive and cytotoxic treatment necessitates increased awareness of this infection. HIV-infection, however, does not appear to increase the risk of developing systemic strongyloidiasis. Patients from endemic areas and travellers to such areas, even in the remote past, should be examined for strongyloidiasis before being given immunosuppressive treatment. Awareness of the possibility of systemic strongyloidiasis is essential if such a patient develops gastrointestinal or pulmonary symptoms or has repeated episodes of unexplained gram-negative infections while undergoing immunosuppressive treatment.


Assuntos
Enteropatias Parasitárias/parasitologia , Strongyloides stercoralis , Estrongiloidíase/parasitologia , Adulto , Ampicilina/uso terapêutico , Animais , Evolução Fatal , Feminino , Gentamicinas/uso terapêutico , Humanos , Enteropatias Parasitárias/complicações , Enteropatias Parasitárias/imunologia , Enteropatias Parasitárias/terapia , Hanseníase Virchowiana/complicações , Strongyloides stercoralis/imunologia , Estrongiloidíase/complicações , Estrongiloidíase/imunologia , Estrongiloidíase/terapia , Tiabendazol/uso terapêutico
4.
Nihon Kyobu Shikkan Gakkai Zasshi ; 32(11): 1078-82, 1994 Nov.
Artigo em Japonês | MEDLINE | ID: mdl-7815761

RESUMO

An 80-year-old blind man with lepromatous leprosy suffered from right femoral neck and humeral neck fractures on July 9, 1993. Because of fever (38.6 degrees C), difficult expectoration and diffuse bilateral perihilar infiltrates with consolidation in the left lower lung field on his chest radiograph, severe pneumonia was diagnosed. With intravenous hyperalimentation, imipenem/cilastatin (IPM/CS), ceftazidime, minocycline, gentamicin (GM), and human immunoglobulin were administrated. On July 29, hip screw-plate fixation was done. Citrobacter freundii was isolated from the sputum and its susceptibility was IPM/CS+, GM3+. Multi-drug therapy with GM and other antibiotics improved the patients' condition, but Citrobacter freundii were still detected and 43 days of medication were needed. According to a report by the Ministry of Health and Welfare in 1992, the resistance rate of IPM/CS against Citrobacter freundii is only 0.7%, and IPM/CS is more effective than beta-Lactams. This is a very rare case of severe pneumonia in an elderly patient caused by Citrobacter freundii that was suspected to have low susceptibility to IPM/CS.


Assuntos
Citrobacter freundii/efeitos dos fármacos , Quimioterapia Combinada/farmacologia , Infecções por Enterobacteriaceae/microbiologia , Pneumonia Bacteriana/microbiologia , Idoso , Idoso de 80 Anos ou mais , Cilastatina/farmacologia , Combinação Imipenem e Cilastatina , Citrobacter freundii/isolamento & purificação , Combinação de Medicamentos , Resistência Microbiana a Medicamentos , Infecções por Enterobacteriaceae/tratamento farmacológico , Gentamicinas/uso terapêutico , Humanos , Imipenem/farmacologia , Masculino , Pneumonia Bacteriana/tratamento farmacológico
5.
Nihon Kyobu Shikkan Gakkai Zasshi ; 32(9): 851-5, 1994 Sep.
Artigo em Japonês | MEDLINE | ID: mdl-7799554

RESUMO

Hospital-acquired pneumonia is one of the most important fatal respiratory diseases in the elderly. Prompt and precise empiric therapy is essential for recovery. Fourteen isolates from twelve elderly lepromatous leprosy patients (9 men, 3 women, mean age of 75.8 years) with hospital-acquired pneumonia were studied. Subsequently, empiric therapy with gentamicin and beta-lactams for nosocomial pneumonia in the elderly was examined. Fourteen types of bacteria isolated from expectorated sputum specimens consisted mainly of ten strains of gram-negative bacilli (71%) six of Klebsiella pneumoniae, one each of Citrobacter freundii, Enterobacter agglomerans, Serratia liquefaciens, and Aeromonas hydrophilia and four strains of gram-positive cocci (29%) two of Staphylococcus sp., one each of Streptococcus sp. and Streptococcus pneumoniae. Methicillin-resistant Staphylococcus aureus and Pseudomonas sp. were not detected. Resistance rates of the etiologic agents to the antibiotics showed that gentamicin was 7.7%, ceftazidime 0%, and cefmetazole 23.1%. Cephalosporins were superior to penicillins. As a result of empiric therapy, six elderly leprosy patients with nosocomial pneumonia were cured and one improved temporarily. This study shows the necessity of specific empiric therapy for hospital-acquired pneumonia in a hospital with many elderly patients. The combination of gentamicin and beta-lactams is of value as an initial antibiotic therapy for hospital-acquired pneumonia in the elderly.


Assuntos
Infecção Hospitalar/microbiologia , Quimioterapia Combinada/uso terapêutico , Hospitais de Dermatologia Sanitária de Patologia Tropical , Hanseníase/complicações , Pneumonia Bacteriana/microbiologia , Idoso , Idoso de 80 Anos ou mais , Antibacterianos/uso terapêutico , Infecção Hospitalar/tratamento farmacológico , Feminino , Gentamicinas/uso terapêutico , Humanos , Lactamas , Masculino , Pessoa de Meia-Idade , Pneumonia Bacteriana/tratamento farmacológico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA